198 related articles for article (PubMed ID: 14534354)
1. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty.
Mager DE; Mascelli MA; Kleiman NS; Fitzgerald DJ; Abernethy DR
J Pharmacol Exp Ther; 2003 Dec; 307(3):969-76. PubMed ID: 14534354
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
Abernethy DR; Pezzullo J; Mascelli MA; Frederick B; Kleiman NS; Freedman J
Clin Pharmacol Ther; 2002 Mar; 71(3):186-95. PubMed ID: 11907493
[TBL] [Abstract][Full Text] [Related]
3. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
[TBL] [Abstract][Full Text] [Related]
5. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
6. Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability.
Urquidi-Macdonald M; Mager DE; Mascelli MA; Frederick B; Freedman J; Fitzgerald DJ; Kleiman NS; Abernethy DR
Clin Pharmacol Ther; 2004 Jan; 75(1):60-9. PubMed ID: 14749692
[TBL] [Abstract][Full Text] [Related]
7. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
[TBL] [Abstract][Full Text] [Related]
8. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
Mazurov AV; Pevzner DV; Antonova OA; Byzova TV; Khaspekova SG; Semenov AV; Vlasik TN; Samko AN; Staroverov II; Ruda MY
Platelets; 2002 Dec; 13(8):465-77. PubMed ID: 12487780
[TBL] [Abstract][Full Text] [Related]
9. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
Mascelli MA; Kleiman NS; Marciniak SJ; Damaraju L; Weisman HF; Jordan RE
Am Heart J; 2000 Apr; 139(4):696-703. PubMed ID: 10740154
[TBL] [Abstract][Full Text] [Related]
11. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
[TBL] [Abstract][Full Text] [Related]
12. Abciximab, ticlopidine, and concomitant abciximab-ticlopidine therapy: ex vivo platelet aggregation inhibition profiles in patients undergoing percutaneous coronary interventions.
Kleiman NS; Grazeiadei N; Maresh K; Taylor RJ; Frederick B; Lance ET; Effron MB; Jordan RE; Mascelli MA
Am Heart J; 2000 Sep; 140(3):492-501. PubMed ID: 10966553
[TBL] [Abstract][Full Text] [Related]
13. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
[TBL] [Abstract][Full Text] [Related]
15. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention.
Cox DS; Kleiman NS; Boyle DA; Aluri J; Parchman LG; Holdbrook F; Fossler MJ
J Clin Pharmacol; 2004 Sep; 44(9):981-90. PubMed ID: 15317826
[TBL] [Abstract][Full Text] [Related]
17. A case of pseudothrombocytopenia after infusion of abciximab in vivo and anticoagulant-independent platelet clumping after rechallenge with abciximab in vitro.
Kozak M; Dovc T; Rozman P; Blinc A
Wien Klin Wochenschr; 2000 Feb; 112(3):138-41. PubMed ID: 10729966
[TBL] [Abstract][Full Text] [Related]
18. PK/PD simulations as a tool for rational design of clinical dosage regimens: an example with Fradafiban.
Brickl R; Heinzel G; Weisenberger H; Schubert H; Rutsch W; Roth W
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):475-80. PubMed ID: 9352399
[TBL] [Abstract][Full Text] [Related]
19. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ; Mehran R; Hooper WC; Moses JW; Weisz G; Collins MB; Lansky AJ; Kreps EM; Leon MB; Stone GW; Dangas G
J Invasive Cardiol; 2010 Jan; 22(1):2-6. PubMed ID: 20048389
[TBL] [Abstract][Full Text] [Related]
20. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL
Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
